Zentalis Pharmaceuticals, Inc. (ZNTL)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, Zentalis Pharmaceuticals, Inc. reported revenue of $0, down 100.0% from the prior year. The company ran a net loss. It held $288.97M in total assets against $72.76M in total liabilities.
Key ratios (FY2025)
-63.4%
Return on equity
-100.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $67.42M | $0 | $0 | — | — | — | — | — |
| Operating Income | -$152.81M | -$191.19M | -$299.51M | -$227.29M | -$216.54M | -$118.79M | -$46.84M | — | — |
| Net Income | -$137.06M | -$165.84M | -$292.19M | -$236.81M | -$158.72M | -$117.84M | -$45.66M | — | — |
| EPS (Diluted) | $-1.91 | $-2.33 | $-4.47 | $-4.48 | $-3.72 | $-4.19 | $-8.16 | — | — |
| Total Assets | $288.97M | $430.34M | $551.69M | $539.31M | $454.51M | $365.56M | $87.48M | — | — |
| Total Liabilities | $72.76M | $93.15M | $114.30M | $105.29M | $90.03M | $32.18M | $19.06M | — | — |
| Shareholders' Equity | $216.20M | $337.19M | $437.39M | $434.02M | $364.48M | $333.38M | -$73.28M | $32.31M | — |
| Cash & Equivalents | $35.99M | $33.90M | $28.04M | $43.07M | $59.71M | $54.95M | $67.25M | — | — |
| Operating Cash Flow | -$125.25M | -$170.86M | -$207.82M | -$163.75M | -$154.09M | -$86.83M | -$39.14M | — | — |
| Capital Expenditures | $0 | $221.0K | $583.0K | $2.55M | $6.11M | $758.0K | $352.0K | — | — |
| Shares Outstanding | 69.09M | 71.28M | 70.77M | 59.28M | 45.49M | 41.04M | — | — | 5.19M |